The male hypogonadism market size has grown strongly in recent years. It will grow from $3.75 billion in 2024 to $3.99 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to aging population, awareness and diagnosis, lifestyle factors, chronic illnesses, treatment seeking behavior.
The male hypogonadism market size is expected to see strong growth in the next few years. It will grow to $5.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising awareness, prevalence of lifestyle-related conditions, innovations in therapies, emphasis on men's health, telemedicine and healthcare accessibility. Major trends in the forecast period include attention to psychological and sexual health, exploration of nutraceuticals and lifestyle interventions, market expansion in emerging economies, collaborative research initiatives, focus on long-term safety and monitoring.
The rising infertility rates are projected to drive growth in the male hypogonadism market in the coming years. Infertility is a condition that affects the male or female reproductive system, defined as the inability to conceive after 12 months or more of regular, unprotected sexual intercourse. Male hypogonadism, which can result in reduced sperm production and infertility, is one potential cause of male infertility. Consequently, the increasing prevalence of male infertility is expected to boost the male hypogonadism market. For instance, in February 2024, the Office for National Statistics, a UK-based government department, reported that the total fertility rate (TFR) in 2022 fell to 1.49 children per woman, down from 1.55 in 2021. Thus, the rising infertility rate is significantly contributing to the growth of the male hypogonadism market.
The rising prevalence of chronic diseases is anticipated to significantly drive the growth of the male hypogonadism market in the future. Chronic diseases are defined as conditions that last for a year or longer and require ongoing medical care, often limiting daily activities or both. Conditions such as obesity, diabetes, and metabolic syndrome frequently disrupt hormone production pathways, leading to a higher incidence of male hypogonadism due to their effects on testosterone synthesis and regulation. For example, in January 2022, the American Cancer Society, a U.S.-based cancer awareness nonprofit organization, estimated that there would be approximately 1.9 million new cancer cases and 609,360 cancer-related deaths in the U.S., equating to about 1,670 deaths daily. Globally, the most prevalent cancers include lung, prostate, colorectal, and breast cancers, which account for 43 percent of all newly diagnosed cases. Therefore, the increasing prevalence of chronic diseases is driving the growth of the male hypogonadism market.
A prominent trend is the increasing popularity of product innovations. Companies within this sector are actively pursuing the development of novel products to maintain their competitive positions. For example, in June 2022, Halozyme, a biotechnology company based in the United States, introduced Tlando, an oral treatment designed for testosterone replacement therapy in male hypogonadism. Tlando, a prescription drug containing testosterone, represents a milestone as the first FDA-approved oral testosterone treatment. Its application is targeted at adult men experiencing low or no testosterone due to specific medical conditions.
Major players in the male hypogonadism market are strategically directing their efforts toward creating innovative products, including digital-forward platforms. These platforms aim to engage patients through telemedicine, provide educational resources, and simplify access to treatments, thereby revolutionizing the care landscape for male hypogonadism while enhancing patient support and treatment accessibility. An illustrative example is Base Healthcare, a U.S.-based men's virtual health platform, which, in October 2022, launched a subscription-based platform exclusively for men. This digital health platform prioritizes fundamental health and hormone enhancement through oral testosterone treatment, offering users convenient access to adequate testosterone therapy (ATT), certified medical professionals, and personalized health guidance.
In July 2022, Gruenenthal, a pharmaceutical company headquartered in Germany, acquired Nebido from Bayer AG for €500 million ($551.32 million). This acquisition is strategically aimed at enhancing Gruenenthal’s profitability and enabling increased investment in research and development to pave the way for the next generation of pain therapies. Bayer AG, a renowned German pharmaceutical company, plays a pivotal role in the male hypogonadism treatment sector, further influencing the market landscape.
Major companies operating in the male hypogonadism market include Pfizer Inc., Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Merck & Co. Inc., Ferring Pharmaceuticals, Finox Biotech AG, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Perrigo Company plc, IBSA Institut Biochimique SA, Sun Pharmaceutical Industries Limited, Glenmark Pharmaceuticals Limited, Antares Pharma Inc., Zydus Cadila LLC, Besins Healthcare Ltd., Clarus Therapeutics Holdings Inc., Foresee Pharmaceuticals Co. Ltd., Lipocine Inc., Myovant Sciences Ltd., Sandoz International GmbH, Shionogi & Co. Ltd., TherapeuticsMD Inc., Viking Therapeutics Inc.
North America was the largest region in the male hypogonadism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the male hypogonadism market report during the forecast period. The regions covered in the male hypogonadism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the male hypogonadism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Male hypogonadism is a condition characterized by insufficient production of the hormone testosterone in the body. Testosterone plays a crucial role as the primary male sex hormone, and its presence is vital for the development and growth of men during puberty.
The main types of male hypogonadism include Klinefelter syndrome, Kallmann syndrome, pituitary disorders, and others. Klinefelter syndrome is a hereditary disorder that manifests in boys when they have an extra copy of the X chromosome at birth. Treatment for male hypogonadism often involves testosterone therapy delivered through various methods such as topical gels, injectables, transdermal patches, and gonadotropin-releasing hormone therapy.
The male hypogonadism market research report is one of a series of new reports that provides male hypogonadism market statistics, including male hypogonadism industry global market size, regional shares, competitors with a male hypogonadism market share, detailed male hypogonadism market segments, market trends, and opportunities, and any further data you may need to thrive in the male hypogonadism industry. This male hypogonadism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The male hypogonadism market includes revenues earned by entities through hormone testing, semen analysis, pituitary imaging, genetic studies, and testicular biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The male hypogonadism market size is expected to see strong growth in the next few years. It will grow to $5.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising awareness, prevalence of lifestyle-related conditions, innovations in therapies, emphasis on men's health, telemedicine and healthcare accessibility. Major trends in the forecast period include attention to psychological and sexual health, exploration of nutraceuticals and lifestyle interventions, market expansion in emerging economies, collaborative research initiatives, focus on long-term safety and monitoring.
The rising infertility rates are projected to drive growth in the male hypogonadism market in the coming years. Infertility is a condition that affects the male or female reproductive system, defined as the inability to conceive after 12 months or more of regular, unprotected sexual intercourse. Male hypogonadism, which can result in reduced sperm production and infertility, is one potential cause of male infertility. Consequently, the increasing prevalence of male infertility is expected to boost the male hypogonadism market. For instance, in February 2024, the Office for National Statistics, a UK-based government department, reported that the total fertility rate (TFR) in 2022 fell to 1.49 children per woman, down from 1.55 in 2021. Thus, the rising infertility rate is significantly contributing to the growth of the male hypogonadism market.
The rising prevalence of chronic diseases is anticipated to significantly drive the growth of the male hypogonadism market in the future. Chronic diseases are defined as conditions that last for a year or longer and require ongoing medical care, often limiting daily activities or both. Conditions such as obesity, diabetes, and metabolic syndrome frequently disrupt hormone production pathways, leading to a higher incidence of male hypogonadism due to their effects on testosterone synthesis and regulation. For example, in January 2022, the American Cancer Society, a U.S.-based cancer awareness nonprofit organization, estimated that there would be approximately 1.9 million new cancer cases and 609,360 cancer-related deaths in the U.S., equating to about 1,670 deaths daily. Globally, the most prevalent cancers include lung, prostate, colorectal, and breast cancers, which account for 43 percent of all newly diagnosed cases. Therefore, the increasing prevalence of chronic diseases is driving the growth of the male hypogonadism market.
A prominent trend is the increasing popularity of product innovations. Companies within this sector are actively pursuing the development of novel products to maintain their competitive positions. For example, in June 2022, Halozyme, a biotechnology company based in the United States, introduced Tlando, an oral treatment designed for testosterone replacement therapy in male hypogonadism. Tlando, a prescription drug containing testosterone, represents a milestone as the first FDA-approved oral testosterone treatment. Its application is targeted at adult men experiencing low or no testosterone due to specific medical conditions.
Major players in the male hypogonadism market are strategically directing their efforts toward creating innovative products, including digital-forward platforms. These platforms aim to engage patients through telemedicine, provide educational resources, and simplify access to treatments, thereby revolutionizing the care landscape for male hypogonadism while enhancing patient support and treatment accessibility. An illustrative example is Base Healthcare, a U.S.-based men's virtual health platform, which, in October 2022, launched a subscription-based platform exclusively for men. This digital health platform prioritizes fundamental health and hormone enhancement through oral testosterone treatment, offering users convenient access to adequate testosterone therapy (ATT), certified medical professionals, and personalized health guidance.
In July 2022, Gruenenthal, a pharmaceutical company headquartered in Germany, acquired Nebido from Bayer AG for €500 million ($551.32 million). This acquisition is strategically aimed at enhancing Gruenenthal’s profitability and enabling increased investment in research and development to pave the way for the next generation of pain therapies. Bayer AG, a renowned German pharmaceutical company, plays a pivotal role in the male hypogonadism treatment sector, further influencing the market landscape.
Major companies operating in the male hypogonadism market include Pfizer Inc., Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Merck & Co. Inc., Ferring Pharmaceuticals, Finox Biotech AG, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Perrigo Company plc, IBSA Institut Biochimique SA, Sun Pharmaceutical Industries Limited, Glenmark Pharmaceuticals Limited, Antares Pharma Inc., Zydus Cadila LLC, Besins Healthcare Ltd., Clarus Therapeutics Holdings Inc., Foresee Pharmaceuticals Co. Ltd., Lipocine Inc., Myovant Sciences Ltd., Sandoz International GmbH, Shionogi & Co. Ltd., TherapeuticsMD Inc., Viking Therapeutics Inc.
North America was the largest region in the male hypogonadism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the male hypogonadism market report during the forecast period. The regions covered in the male hypogonadism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the male hypogonadism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Male hypogonadism is a condition characterized by insufficient production of the hormone testosterone in the body. Testosterone plays a crucial role as the primary male sex hormone, and its presence is vital for the development and growth of men during puberty.
The main types of male hypogonadism include Klinefelter syndrome, Kallmann syndrome, pituitary disorders, and others. Klinefelter syndrome is a hereditary disorder that manifests in boys when they have an extra copy of the X chromosome at birth. Treatment for male hypogonadism often involves testosterone therapy delivered through various methods such as topical gels, injectables, transdermal patches, and gonadotropin-releasing hormone therapy.
The male hypogonadism market research report is one of a series of new reports that provides male hypogonadism market statistics, including male hypogonadism industry global market size, regional shares, competitors with a male hypogonadism market share, detailed male hypogonadism market segments, market trends, and opportunities, and any further data you may need to thrive in the male hypogonadism industry. This male hypogonadism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The male hypogonadism market includes revenues earned by entities through hormone testing, semen analysis, pituitary imaging, genetic studies, and testicular biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Male Hypogonadism Market Characteristics3. Male Hypogonadism Market Trends and Strategies4. Male Hypogonadism Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Male Hypogonadism Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Male Hypogonadism Market34. Recent Developments in the Male Hypogonadism Market
5. Global Male Hypogonadism Growth Analysis and Strategic Analysis Framework
6. Male Hypogonadism Market Segmentation
7. Male Hypogonadism Market Regional and Country Analysis
8. Asia-Pacific Male Hypogonadism Market
9. China Male Hypogonadism Market
10. India Male Hypogonadism Market
11. Japan Male Hypogonadism Market
12. Australia Male Hypogonadism Market
13. Indonesia Male Hypogonadism Market
14. South Korea Male Hypogonadism Market
15. Western Europe Male Hypogonadism Market
16. UK Male Hypogonadism Market
17. Germany Male Hypogonadism Market
18. France Male Hypogonadism Market
19. Italy Male Hypogonadism Market
20. Spain Male Hypogonadism Market
21. Eastern Europe Male Hypogonadism Market
22. Russia Male Hypogonadism Market
23. North America Male Hypogonadism Market
24. USA Male Hypogonadism Market
25. Canada Male Hypogonadism Market
26. South America Male Hypogonadism Market
27. Brazil Male Hypogonadism Market
28. Middle East Male Hypogonadism Market
29. Africa Male Hypogonadism Market
30. Male Hypogonadism Market Competitive Landscape and Company Profiles
31. Male Hypogonadism Market Other Major and Innovative Companies
35. Male Hypogonadism Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Male Hypogonadism Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on male hypogonadism market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for male hypogonadism ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The male hypogonadism market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- the market characteristics section of the report defines and explains the market.
- the market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- the forecasts are made after considering the major factors currently impacting the market. These include:
- the forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- the regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- the competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- the trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Type: Klinefelters Syndrome; Kallmann Syndrome; Pituitary Disorders; Other Types2) by Drug Delivery: Topical Gels; Injectables; Transdermal Patches; Other Drug Deliveries
3) by Therapy: Testosterone Therapy; Gonadotropin-Releasing Hormone Therapy
Subsegments:
1) by Klinefelter's Syndrome: 47,XXY Syndrome; Other Variants2) by Kallmann Syndrome: Isolated Kallmann Syndrome; Syndromic Kallmann Syndrome
3) by Pituitary Disorders: Hypopituitarism; Pituitary Tumors; Other Pituitary Disorders
4) by Other Types: Androgen Insensitivity Syndrome; Testicular Dysgenesis Syndrome; Genetic Mutations and Disorders
Key Companies Mentioned: Pfizer Inc.; Bayer AG; Eli Lilly and Company Ltd.; Endo International plc.; Merck & Co. Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Male Hypogonadism market report include:- Pfizer Inc.
- Bayer AG
- Eli Lilly and Company Ltd.
- Endo International plc.
- Merck & Co. Inc.
- Ferring Pharmaceuticals
- Finox Biotech AG
- Teva Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Perrigo Company plc
- IBSA Institut Biochimique SA
- Sun Pharmaceutical Industries Limited
- Glenmark Pharmaceuticals Limited
- Antares Pharma Inc.
- Zydus Cadila LLC
- Besins Healthcare Ltd.
- Clarus Therapeutics Holdings Inc.
- Foresee Pharmaceuticals Co. Ltd.
- Lipocine Inc.
- Myovant Sciences Ltd.
- Sandoz International GmbH
- Shionogi & Co. Ltd.
- TherapeuticsMD Inc.
- Viking Therapeutics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 3.99 Billion |
| Forecasted Market Value ( USD | $ 5.08 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
